Core Insights - Versant Ventures has launched Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for serious diseases [1] - The company has secured over $70 million in committed funding, including a $50 million upfront capital collaboration with Biogen Inc. [1] - Dayra Therapeutics emerged from Versant's Frontier Discovery Engine, which operates in Toronto and Montreal [1]

Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop oral macrocycl ...

The drugmaker announces that Ozempic didn't slow the progression of Alzheimer's in two clinical trials. ...

诺和诺德的竞争对手渤健(BIIB.US)盘前拉升涨超6%。消息面上，诺和诺德公司称Evoke 3期试验未显示阿尔茨海默病进展的统计学显著减少。 ...

尽管这一消息被视为阿尔茨海默症患者的福音，但Aducanumab跳过二期试验的非连续性数据和自相矛 盾的实验结果还是让这一决定备受争议。 不过，对于业界争议，FDA并非充耳不闻。根据"加速审批"的规则，FDA要求渤健进行新的随机对照临 床试验以验证临床效益。如果该试验未能验证临床效益，FDA可能会启动程序，撤销对该药物的批准。 全文链接：最被患者期待，最受业界争议：FDA十八年后再批阿尔茨海默药，百亿美元市场引关注 每经记者｜金喆 实习生 林姿辰 每经编辑｜宋思艰 当地时间6月7日，FDA宣布批准渤健/卫材公司Aβ（β淀粉样蛋白）抗体Aduhelm（Aducanumab）用于 治疗早期阿尔茨海默症患者的生物制品许可申请，这是继2003年后FDA批准的首款阿尔茨海默药。 ...

每经记者｜金喆 每经实习记者｜许立波 林姿辰 每经编辑｜宋思艰 到了审批期的最后一个月，美国食品药品监督管理局（FDA）还是决定对这个全球首款延缓阿尔茨海默 症进程的新药放行。 当地时间6月7日，FDA宣布批准渤健/卫材公司Aβ（β淀粉样蛋白）抗体Aduhelm（Aducanumab）用于 治疗早期阿尔茨海默症（AD）患者的生物制品许可（BLA）申请，这是继2003年后FDA批准的首款阿 尔茨海默药。 消息传出后，渤健股价一度暴涨近60%，国内资本市场也跃跃欲试，绿谷制药等多家布局阿尔茨海默病 的国内企业备受市场关注。 不过，《每日经济新闻》记者注意到，与资本市场的热情不同，业界对这款药的态度"冰火两重天"。回 望此前国内获批的阿尔兹海默药，也难逃被质疑的命运。 靶向Aβ药加速审批，临床效益仍需验证 本次Aducanumab获批之所以引爆舆论，或许主要因为两个因素，一个是阿尔茨海默症本身的热度，另 一个是其一波三折的上市之路。 阿尔茨海默病（AD）又称老年痴呆症，是一种起病隐匿的进行性发展的神经系统退行性疾病。根据世 界卫生组织估计，目前全球约有3500万至5000万阿尔茨海默症患者，并且每年预计将有1000 ...

格隆汇11月21日｜TELSEY咨询集团将沃尔玛目标价格从118美元上调至130美元，将渤健目标价从118 美元上调至157美元。 ...

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clini ...

High-rolling investors have positioned themselves bullish on Biogen (NASDAQ:BIIB), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in BIIB often signals that someone has privileged information.Today, Benzinga's options scanner spotted 8 options trades for Biogen. This is not a typical pattern.The sentiment among these major ...

With a market cap of $24.6 billion, Biogen Inc. (BIIB) is a global biotechnology leader specializing in therapies for neurological and neurodegenerative diseases. Its portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Avonex, Plegridy, and Tysabri, as well as Spinraza for spinal muscular atrophy and several biosimilars. Shares of the Cambridge, Massachusetts-based company have underperformed the broader market over the past 52 weeks. BIIB stock has risen 1.6% over this time fram ...